Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03322995 · ClinicalTrials.gov registry record · Phase 2
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
A Phase 2 study of Pancreatic Cancer, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT03322995: Recruiting Phase 2 study of Pancreatic Cancer, sponsored by Medical College of Wisconsin.
NCT03322995 is a Phase 2 study of Pancreatic Cancer that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 125 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03322995, a Phase 2 study of Pancreatic Cancer, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.
Primary Outcome
This measure is the number of subjects completing all intended neoadjuvant therapy and surgical therapy.
Conditions Studied
Interventions
- RADIATION Chemoradiation
- DRUG First-line Chemotherapy
- DRUG Second-line Chemotherapy
Study Locations (1)
Wisconsin
- Froedtert & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2018-06-21 |
| Est. Completion | 2032-06-01 |
| Phase | Phase 2 |
What NCT03322995 shows while recruiting
NCT03322995 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Chemoradiation is the first listed.
NCT03322995 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03322995 about?
NCT03322995 is a clinical study titled "Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial". This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.
What is the current status of trial NCT03322995?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2018-06-21. Estimated completion is 2032-06-01.
What conditions does trial NCT03322995 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT03322995?
The interventions under investigation include: Chemoradiation (RADIATION), First-line Chemotherapy (DRUG), Second-line Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT03322995?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03322995 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03322995's enrollment target sits among peer trials
125 90th of 278 higher than 187 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI